Global Patent Index - EP 0452598 B1

EP 0452598 B1 19931124 - Use of a polypeptide having interleukin-2 activity for the preparation of a pharmaceutical composition for the treatment of simple pleura cancer.

Title (en)

Use of a polypeptide having interleukin-2 activity for the preparation of a pharmaceutical composition for the treatment of simple pleura cancer.

Title (de)

Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.

Title (fr)

Utilisation d'un polypeptide ayant l'activité de l'interleukine 2 humaine pour préparer une composition pharmaceutique destinée au traitement de cancers primitifs de la plèvre.

Publication

EP 0452598 B1 19931124 (FR)

Application

EP 90401533 A 19900606

Priority

FR 9004895 A 19900417

Abstract (en)

[origin: EP0452598A1] The use of a polypeptide (I) with human interleukin 2 activity is claimed for treating primary cancers of the pleura, especially mesothelioma. Pref. (I) is a pure recombinant IL-2, especially in the non-glycosylated reduced form.

IPC 1-7

A61K 37/02

IPC 8 full level

A61K 38/00 (2006.01); A61K 38/20 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP KR US)

A61K 38/00 (2013.01 - KR); A61K 38/2013 (2013.01 - EP US); A61P 35/00 (2017.12 - EP)

Citation (examination)

  • PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol.31, mars 1990, page 275, résumé no. 1630; G.STOTER et al.: "Intrapleural interleukin-2 (IL-2) in malignant pleural mesothelioma: A phase I-II study"
  • PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 31, mars 1990, page 274, résumé no. 1622; J.-C. LOURANT et al.: "Cytotoxic response of blood lymphocytus from patients with meligament pleurel effusions treated with intro pleural introleukin-2"
  • NATURAL IMMUNITY AND CELL GROWTH REGULATION, vol. 9, no.2, mars-avril 1990, page 74; A.M.M. EGGERMONT et al.: "Intrapleural administration of recombinant interleukin-2 (IL.2) in patients with malignant pleural mesothelioma: A phase I-II study"
  • CANCER TREATMENT REVIEWS, vol. 16, suppl. A, 1989, pages 161-162, Academic Press Ltd; N. THATCHER et al.: "Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results"
  • REV. PHNEUMOL. CLIN., vol. 46, no. 5, 1990; C. BOUTIN et al.: "Le traitement des mésothéliomes par interféron gamma et interleukine 2"

Designated contracting state (EPC)

AT BE CH DE DK FR GB IT LI LU NL SE

DOCDB simple family (publication)

EP 0452598 A1 19911023; EP 0452598 B1 19931124; AT E97575 T1 19931215; AU 5693590 A 19911121; AU 631649 B2 19921203; CA 2018630 A1 19911017; DE 69004794 D1 19940105; DE 69004794 T2 19940414; DK 0452598 T3 19940117; FR 2660863 A1 19911018; FR 2660863 B1 19940121; HU 205261 B 19920428; HU 903769 D0 19901128; HU T56721 A 19911028; JP 2848922 B2 19990120; JP H045241 A 19920109; KR 0165674 B1 19990115; KR 910018038 A 19911130; OA 09213 A 19920630; US 5219565 A 19930615; ZA 904353 B 19910828

DOCDB simple family (application)

EP 90401533 A 19900606; AT 90401533 T 19900606; AU 5693590 A 19900608; CA 2018630 A 19900608; DE 69004794 T 19900606; DK 90401533 T 19900606; FR 9004895 A 19900417; HU 376990 A 19900608; JP 14753690 A 19900607; KR 900008407 A 19900608; OA 59802 A 19900608; US 53577590 A 19900608; ZA 904353 A 19900606